When one partner takes PrEP consistently, the HIV-negative partner who is not on PrEP gets no direct pharmacological protection from it. PrEP shields the person swallowing the pill (or receiving the injection), not the person next to them. That said, the protection it gives the user is substantial: across randomized trials, oral PrEP reduced the risk of HIV acquisition by about half in intention-to-treat analyses, and by upwards of 90% among people with confirmed high adherence.1PubMed Central. Effectiveness of Pre-Exposure Prophylaxis (PrEP) in the Prevention of Human Immunodeficiency Virus (HIV): A Systematic Review of Randomized Controlled Trials With Narrative Synthesis So the person on PrEP is well protected, but the question of whether the other partner is “safe” depends on which direction the risk flows, what other infections are in play, and how reliably the medication is actually taken.
PrEP Protects the User, Not the Partner
PrEP works by flooding certain tissues with antiretroviral drugs before HIV has a chance to establish itself. It builds a chemical barrier inside the body of the person taking it. If you are not the one taking PrEP, that barrier does not exist in your cells. This means the answer to the title question splits depending on the couple’s situation. In a serodiscordant couple where one partner is HIV-positive and the other is negative and on PrEP, the negative partner is protected. But if the roles are reversed and the HIV-negative partner is not taking PrEP, that person has no drug-mediated defense regardless of what their partner does.
This distinction matters because many people conflate PrEP with condoms. A condom sits between two people, so both benefit. PrEP is more like a vaccine in its logic: it arms one immune system, and only that one. When couples discuss their prevention strategy, this asymmetry is the first thing to get right.
How Much Protection Does the Person on PrEP Actually Get?
A meta-analysis of placebo-controlled trials found that oral PrEP (tenofovir-based) reduced HIV risk by roughly 51% overall.2PubMed Central. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations That number sounds modest, but it reflects the messy reality of clinical trials where many participants did not take the pills consistently. Among those who actually had detectable drug levels in their blood, protection jumped dramatically, reaching 92–99% in some trial subgroups with confirmed adherence.1PubMed Central. Effectiveness of Pre-Exposure Prophylaxis (PrEP) in the Prevention of Human Immunodeficiency Virus (HIV): A Systematic Review of Randomized Controlled Trials With Narrative Synthesis
Injectable cabotegravir, a newer long-acting formulation given every two months, sidesteps the adherence problem almost entirely. In head-to-head trials comparing it to daily oral PrEP, the injectable version reduced HIV incidence by about 65–79% more than the oral pill.3PubMed Central. Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition In one large trial among cisgender men and transgender women who have sex with men, HIV incidence was roughly 0.4 per 100 person-years on the injection versus 1.3 per 100 person-years on the daily pill.4The Lancet HIV. Efficacy and safety of long-acting injectable cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine for HIV prevention in cisgender men and transgender women who have sex with men (HPTN 083) The injectable version works so well largely because you cannot forget to take it between clinic visits.
Adherence Is Where the Gap Lives
The difference between PrEP working brilliantly and PrEP working only modestly comes down almost entirely to whether the person takes it. A modeling study estimated that for cisgender women, taking two pills a week cut HIV incidence by about 59%, four pills a week by about 84%, and a full seven days a week by about 96%.5PubMed Central. Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence The curve is steep: each missed day matters more than you would expect, and partial adherence in women appears less forgiving than in men. One reason is that drug concentrations in vaginal tissue are considerably lower than in rectal tissue, so the margin for missed doses is thinner.6PubMed Central. HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention
If your partner tells you they are on PrEP but their adherence is spotty, their protection level could be much lower than you both assume. And you, as the non-PrEP partner, still have zero drug-based protection. This is not a reason to be suspicious of your partner, but it is a reason why relying entirely on one person’s medication use is a shakier strategy than it sounds on paper.
Event-Driven Dosing and Its Real-World Track Record
Some people take PrEP only around the times they expect to have sex, often called “on-demand” or event-driven dosing (a 2-1-1 schedule: two pills before, one the next day, and one the day after that). In controlled trials, this approach covered sexual encounters about as well as daily dosing. One randomized crossover trial found that 92% of condomless anal intercourse was covered under both daily and on-demand schedules.7Wiley Online Library. Comparison between daily and on-demand PrEP (pre-exposure prophylaxis) regimen in covering condomless anal intercourse for men who have sex with men in Hong Kong
In real-world practice, though, the picture is less rosy. A large Dutch study covering over 41,000 person-years found that HIV incidence was about seven times higher among event-driven users than among daily users.8medRxiv. Increased HIV incidence during Event-Driven PrEP compared to Daily PrEP in the Netherlands Overall incidence was still low in both groups, but the gap was striking. The likely explanation is that real life is not a clinical trial: people have unplanned encounters, miscalculate timing, or skip the follow-up doses. If your partner is using event-driven PrEP, it is worth understanding that this method demands precise timing and that real-world effectiveness can fall short of clinical-trial performance.
Breakthrough Infections Happen, But They Are Rare
Even with perfect adherence, PrEP is not 100% effective. A narrative review found that seroconversions during high-adherence PrEP use, while extremely rare, do occur.9PubMed Central. Breakthrough Acute HIV Infections among Pre-Exposure Prophylaxis Users with High Adherence: A Narrative Review A separate review identified ten cases of “true” PrEP failure where adherence was well-documented through blood or hair analysis. All ten involved continued condomless anal sex, and there was a strong association with recurrent sexually transmitted infections and with acquiring a strain of HIV that already carried resistance to the PrEP drugs.10PubMed. A review of reported cases of HIV pre-exposure prophylaxis failure with resultant breakthrough HIV infections
That last point is worth sitting with. Drug-resistant strains of HIV can slip past PrEP’s defenses even when drug levels are adequate. Seroconversion in these cases was often atypical or delayed, meaning the person tested negative for longer than usual, which made diagnosis harder. For the partner who is not on PrEP, this is another reminder that their own risk is not reduced by someone else’s medication.
PrEP Does Nothing for Other STIs
PrEP’s mechanism targets HIV and HIV alone. It has no effect on syphilis, gonorrhea, chlamydia, herpes, or HPV.11The Brazilian Journal of Infectious Diseases. EFFECTIVENESS OF PREP IN THE PREVENTION OF STIS: A META-ANALYSIS OF BREAKTHROUGH CASES And the data on STI rates among PrEP users are sobering: roughly one in four PrEP users has a curable bacterial STI at any given time.12PubMed Central. Challenges and Solutions to STI Control in the Era of HIV and STI Prophylaxis
Part of this stems from the populations who use PrEP: they tend to be sexually active people who were already at higher risk for STIs. But condom use also drops significantly after people start PrEP. One study found that about 78% of PrEP users reported decreased condom use for anal intercourse after starting the medication.13PLOS ONE. Low use of condom and high STI incidence among men who have sex with men in PrEP programs A Danish study found STI incidence rose after PrEP initiation, though the increase actually began ten to twenty weeks before PrEP was started, suggesting that behavioral shifts preceded the prescription rather than being caused by it.14PubMed Central. Questioning risk compensation: pre-exposure prophylaxis (PrEP) and sexually transmitted infections among men who have sex with men, capital region of Denmark, 2019 to 2022
For the partner who is not on PrEP, this matters directly. If your partner’s PrEP use has led to less condom use in the relationship, your exposure to non-HIV STIs may have gone up. An emerging tool called doxycycline post-exposure prophylaxis (doxy-PEP), where you take an antibiotic shortly after sex, has shown reductions of 70–85% in chlamydia and syphilis incidence.15International Journal of Scientific Interdisciplinary Research. INTEGRATION OF STI PREVENTION INTERVENTIONS WITHIN PrEP SERVICE DELIVERY: IMPACT ON STI RATES AND ANTIBIOTIC RESISTANCE But doxy-PEP raises its own concerns about antibiotic resistance, and it does not cover gonorrhea as reliably.
The U=U Factor and Serodiscordant Couples
If the HIV-positive partner in a couple is on effective antiretroviral treatment and has an undetectable viral load, the principle of Undetectable = Untransmittable (U=U) comes into play. This is one of the strongest findings in modern HIV science: large studies involving thousands of serodiscordant couples found zero linked transmissions when the positive partner maintained viral suppression. In this scenario, the negative partner’s risk from their HIV-positive partner approaches zero whether or not anyone is on PrEP.
Some clinical guidelines in serodiscordant couples recommend continuing PrEP until the positive partner has achieved stable viral suppression, then reassessing.16PubMed Central. ” I just believe there is a risk ” understanding of undetectable equals untransmissible (U = U) among health providers and HIV‐negative partners in serodiscordant relationships in Kenya The real-world challenge is trust and verification: viral load can fluctuate, treatment interruptions happen, and not everyone has perfect awareness of their partner’s lab results. Even with U=U in effect and PrEP protecting the negative partner, some couples who are trying to conceive have opted for additional measures like semen washing to eliminate even a negligible residual risk.17PubMed Central. Semen Washing and Intrauterine Insemination for Reducing the Risk of Human Immunodeficiency Virus Transmission in Serodiscordant Couples
Regular Testing Is Part of the Deal
Guidelines recommend that people on oral PrEP get an HIV test every three months. In practice, a national assessment of U.S. PrEP users found that about a quarter of PrEP prescription fills occurred without any type of HIV test in the prior three months, and roughly 8% occurred without any HIV test in the prior year.18Oxford Academic (Open Forum Infectious Diseases). High Rates of Missed HIV Testing Among Oral PrEP Users in the United States From 2018-2021 This is a problem for the person on PrEP, because taking PrEP while unknowingly HIV-positive can drive drug resistance. But it is also a problem for their partner: if the PrEP user acquired HIV through a breakthrough infection and does not know it, they could transmit the virus during the window before diagnosis. Regular testing is not optional; it is structural to how PrEP works safely.
How Relationship Dynamics Shape PrEP Decisions
PrEP does not exist in a vacuum. It lands in the middle of a relationship with its own power dynamics, trust level, and sexual agreements. Among same-sex male couples in one U.S. study, roughly 80% of those who believed their partner would not support PrEP use cited being in a monogamous relationship as the reason, and about 45% worried their partner would interpret PrEP as evidence of cheating.19PubMed Central. The influence of relationship dynamics and sexual agreements on perceived partner support and benefit of PrEP use among same-sex male couples in the U.S. Couples with explicit agreements allowing outside partnerships, and those with stronger collaborative communication, were significantly more likely to see PrEP as a shared benefit rather than a threat.
Separate qualitative research found that couples using PrEP often showed heightened trust and communication, particularly when establishing open sexual agreements.20PubMed Central. Negotiating sexual safety in the era of biomedical HIV prevention: relationship dynamics among male couples using pre-exposure prophylaxis PrEP, in these cases, was less about the pill itself and more about the conversations it prompted. For the partner not on PrEP, understanding why your partner is taking it and whether it changes what you are both doing (or not doing) to stay safe is the real question.
PrEP and Gender-Affirming Hormones
Transgender women on feminizing hormone therapy sometimes worry that hormones could reduce PrEP’s effectiveness, or vice versa. The concern is not unfounded: some studies have found that feminizing hormones reduce the plasma concentration of tenofovir. But the intracellular levels of the drug’s active form remained above the threshold needed for protection, and no clinically meaningful drug interactions have been demonstrated.21PubMed. Drug-drug interactions between gender-affirming hormone therapy and antiretrovirals for treatment/prevention of HIV A subanalysis from the DISCOVER trial confirmed that drug levels in transgender women on hormone therapy were comparable to those in cisgender men, regardless of whether they were on the older or newer oral PrEP formulation.22PubMed Central. Gender Affirming Hormones Do Not Affect the Exposure and Efficacy of F/TDF or F/TAF for HIV Preexposure Prophylaxis Masculinizing hormones similarly showed no meaningful interaction. PrEP does not affect hormone levels, and hormones do not undermine PrEP.
Trying to Conceive in a Serodiscordant Couple
For couples where one partner is HIV-positive and the other is negative, PrEP has become an important tool for safer conception. Data from a randomized trial found no increase in pregnancy loss, birth defects, preterm birth, or infant growth problems when the HIV-negative partner (male or female) used PrEP around the time of conception.23PubMed Central. PrEP as peri-conception HIV prevention for women and men Among Kenyan women who used PrEP during pregnancy, almost all reported minimal side effects limited to the early weeks, and the experience of staying HIV-negative throughout pregnancy reinforced their confidence in the drug’s safety.24PubMed Central. “I did not want to give birth to a child who has HIV”: Experiences using PrEP during pregnancy among HIV-uninfected Kenyan women in HIV-serodiscordant couples In this context, PrEP directly protects the negative partner who is trying to become pregnant. The partner on treatment for HIV contributes through viral suppression, and PrEP adds a second line of defense during the window of exposure.
The Vaginal Ring and Other Options on the Horizon
Not everyone wants to take a daily pill or get an injection every two months. The dapivirine vaginal ring, designed for women, provides continuous slow-release of an antiretroviral drug over a month. In two large trials, it reduced HIV incidence by about 27–31%, with protection climbing to roughly 56% among women over 21 who used it more consistently.25PubMed. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women 26PubMed. Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women In an open-label extension, where women chose to use the ring rather than being randomized, adherence was higher and HIV incidence dropped by roughly 62% compared to what would be expected without the ring.27The Lancet HIV. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM)
These numbers are lower than daily oral PrEP or injectable cabotegravir, but the ring fills an important niche. It is discreet, self-administered, and does not require daily action. For women in settings where they may not have the autonomy to negotiate condom use or disclose PrEP pill-taking to a partner, the ring can be a quietly powerful tool. And like oral PrEP, it protects only the person using it.
Who Gets PrEP and Who Does Not
Even when both partners want PrEP, access is not evenly distributed. In the United States, PrEP uptake relative to need has been consistently highest among White individuals, intermediate for Hispanic individuals, and lowest for Black individuals, across every region and every year since PrEP became available.28The Lancet Regional Health – Americas. Equity of PrEP uptake by race, ethnicity, sex and region in the United States in the first decade of PrEP Race was a stronger predictor of PrEP access than geography: White residents in the South, the region with the lowest overall PrEP use, still had higher uptake than Black residents in the Northeast, the region with the highest. Among those who did access PrEP, White users filled prescriptions for more days per year (a median of 290 days) than Hispanic users (268 days) or Black users (251 days), and younger users had substantially lower coverage than older ones.29PubMed Central. Inequities in PrEP annualized pill-day coverage, United States, 2018-2022
These disparities mean the question “is the other partner safe?” lands differently depending on who you are and where you live. If one partner faces structural barriers to getting PrEP or maintaining consistent access, the couple’s overall prevention strategy needs to account for that gap rather than assume the medication will be continuously available.